Title: Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate,
and tenofovir alafenamide fumarate in patients with hepatitis B: A network meta-analysis
Version: 1 Date: 19 May 2023
Reviewer's report:
There are some comments:
Results
There is no forest plot in the Results section. Could you please explain the reason?
The duration of the studies is different. And there is no subgroup analysis about it.
Conclusion
The conclusion of this study has been suggested by the most updated guidelines. According
to AASLD 2018 Hepatitis B Guidance, TAF is associated with lower rates of bone and renal
abnormalities than TDF; In cases of suspected TDF-associated renal dysfunction and/or bone
disease, TDF should be discontinued and substituted with TAF or entecavir. And according
to EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection,
patients on TDF at risk of development and/or with underlying renal or bone disease should be
considered for a switch to ETV or TAF.
Check the data in the tables and the full text.
In the duration part of Table 1, there are some studies with years. However, there are some
studies with numbers only.
In Synthesis of results section, you said “ETV reduced eGFR less than TDF, SMD=3.60
(95%Cl:1.94~5.26), which was statistically significant. TAF reduced eGFR less than TDF,
SMD=4.27 (95%Cl:2.62~5.93)”. SMD should be -3.60 and -4.27. The same questions are also
observed in Bone events section.
Check the grammar and language carefully.
In Introduction section, you said “Introductiong”, the spelling of introduction is not right.
In the first paragraph of Introduction section, you said “More than 257 million people worldwide
are chronically infected with hepatitis B and more than 887,000 people die from HBV infection
each year.” Could you make sure that the number is the same each year?
In the first paragraph of Discussion section, you said “At present, nucleoside analogues have
become the international consensus for the first-line treatment of chronic hepatitis B.” The
nucleoside analogues for HBV treatment include lamivudine, adefovir dipivoxil, entecavir,
telbivudine, TDF and TAF. However, the first-line treatment of chronic hepatitis B is entecavir,
TDF and TAF.
In the third paragraph of Discussion section, you said “Previous studies have shown that TAF
has higher plasma stability than TDF, because both TDF and TAF are precursors of Tenofovir”.
The first letter of tenofovir should be lower-case.
Title: Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate,
and tenofovir alafenamide fumarate in patients with hepatitis B: A network meta-analysis
Version: 1 Date: 19 May 2023
Reviewer's report:
There are some comments:
Results
There is no forest plot in the Results section. Could you please explain the reason?
The duration of the studies is different. And there is no subgroup analysis about it.
Conclusion
The conclusion of this study has been suggested by the most updated guidelines. According
to AASLD 2018 Hepatitis B Guidance, TAF is associated with lower rates of bone and renal
abnormalities than TDF; In cases of suspected TDF-associated renal dysfunction and/or bone
disease, TDF should be discontinued and substituted with TAF or entecavir. And according
to EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection,
patients on TDF at risk of development and/or with underlying renal or bone disease should be
considered for a switch to ETV or TAF.
Check the data in the tables and the full text.
In the duration part of Table 1, there are some studies with years. However, there are some
studies with numbers only.
In Synthesis of results section, you said “ETV reduced eGFR less than TDF, SMD=3.60
(95%Cl:1.94~5.26), which was statistically significant. TAF reduced eGFR less than TDF,
SMD=4.27 (95%Cl:2.62~5.93)”. SMD should be -3.60 and -4.27. The same questions are also
observed in Bone events section.
Check the grammar and language carefully.
In Introduction section, you said “Introductiong”, the spelling of introduction is not right.
In the first paragraph of Introduction section, you said “More than 257 million people worldwide
are chronically infected with hepatitis B and more than 887,000 people die from HBV infection
each year.” Could you make sure that the number is the same each year?
In the first paragraph of Discussion section, you said “At present, nucleoside analogues have
become the international consensus for the first-line treatment of chronic hepatitis B.” The
nucleoside analogues for HBV treatment include lamivudine, adefovir dipivoxil, entecavir,
telbivudine, TDF and TAF. However, the first-line treatment of chronic hepatitis B is entecavir,
TDF and TAF.
In the third paragraph of Discussion section, you said “Previous studies have shown that TAF
has higher plasma stability than TDF, because both TDF and TAF are precursors of Tenofovir”.
The first letter of tenofovir should be lower-case.
Please review this paper.
user
Title: Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate,
and tenofovir alafenamide fumarate in patients with hepatitis B: A network meta-analysis
Version: 1 Date: 19 May 2023
Reviewer's report:
There are some comments:
Results
There is no forest plot in the Results section. Could you please explain the reason?
The duration of the studies is different. And there is no subgroup analysis about it.
Conclusion
The conclusion of this study has been suggested by the most updated guidelines. According
to AASLD 2018 Hepatitis B Guidance, TAF is associated with lower rates of bone and renal
abnormalities than TDF; In cases of suspected TDF-associated renal dysfunction and/or bone
disease, TDF should be discontinued and substituted with TAF or entecavir. And according
to EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection,
patients on TDF at risk of development and/or with underlying renal or bone disease should be
considered for a switch to ETV or TAF.
Check the data in the tables and the full text.
In the duration part of Table 1, there are some studies with years. However, there are some
studies with numbers only.
In Synthesis of results section, you said “ETV reduced eGFR less than TDF, SMD=3.60
(95%Cl:1.94~5.26), which was statistically significant. TAF reduced eGFR less than TDF,
SMD=4.27 (95%Cl:2.62~5.93)”. SMD should be -3.60 and -4.27. The same questions are also
observed in Bone events section.
Check the grammar and language carefully.
In Introduction section, you said “Introductiong”, the spelling of introduction is not right.
In the first paragraph of Introduction section, you said “More than 257 million people worldwide
are chronically infected with hepatitis B and more than 887,000 people die from HBV infection
each year.” Could you make sure that the number is the same each year?
In the first paragraph of Discussion section, you said “At present, nucleoside analogues have
become the international consensus for the first-line treatment of chronic hepatitis B.” The
nucleoside analogues for HBV treatment include lamivudine, adefovir dipivoxil, entecavir,
telbivudine, TDF and TAF. However, the first-line treatment of chronic hepatitis B is entecavir,
TDF and TAF.
In the third paragraph of Discussion section, you said “Previous studies have shown that TAF
has higher plasma stability than TDF, because both TDF and TAF are precursors of Tenofovir”.
The first letter of tenofovir should be lower-case.
assistant